Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This Item 5.07 disclosure reports the results of Solid Power's 2026 annual meeting of stockholders held on May 20, 2026, including election of three Class II directors (Steven Goldberg, Aleksandra Miziolek, and MaryAnn Wright), ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed voting tallies for each matter are provided, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 8.01
The disclosure announces EXIM Board approval of a $2.9 billion senior secured long-term loan to support development of the Stibnite Gold Project. While this is a material financing event that would significantly affect investor assessment of the company's capital structure and project funding, it does not fit cleanly into the standard M&A taxonomy categories. The event is neither a traditional acquisition/disposition nor a debt covenant breach or going-concern disclosure, making "other_material" the most appropriate classification for this major project financing approval.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
Target Hospitality Corp. held its 2026 Annual Meeting of Stockholders on May 21, 2026, with shareholders voting on four proposals: election of six directors, ratification of Ernst & Young LLP as independent auditor, advisory say-on-pay vote on named executive officer compensation, and approval of a 4,000,000 share increase to the 2019 Incentive Award Plan. All proposals passed with substantial majorities ranging from 85.45% to 99.95% approval.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 85%
filed 2026-05-21
Item 8.01
On May 21, 2026, Target Hospitality Corp. awarded restricted stock units (RSUs) to non-employee directors, with the award agreement filed as an exhibit. This material equity compensation grant to directors reflects the company's director compensation arrangements.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
Mohawk Industries held its Annual Meeting on May 21, 2026, with shareholders voting on four matters: election of three directors, ratification of KPMG LLP as independent auditor, advisory vote on named executive officer compensation, and approval of the 2026 Incentive Plan.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
Rithm Capital held its Annual Meeting of Stockholders with voting results on multiple matters: election of two Class I directors (David Saltzman and William D. Addas), ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and approval of the First Amendment to the 2023 Omnibus Incentive Plan increasing reserved shares by 35 million.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
Citigroup held its 2026 Annual Meeting of Stockholders on May 20, 2026, with voting results disclosed on four matters: election of 13 directors, ratification of KPMG LLP as independent auditor, advisory vote on 2025 executive compensation, and approval of an amendment to the 2019 Stock Incentive Plan increasing authorized shares by 20 million.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-21
Item 8.01
The Company entered into a new $1.2 billion Five-Year Revolving Credit Agreement on May 15, 2026, replacing a prior $1.0 billion facility. While this represents a material refinancing and increase in available liquidity, it does not fit neatly into the more specific event categories (ma_activity applies to acquisitions/dispositions, not credit facility amendments; covenant_breach applies to violations, not new covenant establishment). The disclosure is material to investors as it affects the Company's financial flexibility and capital structure, but the event is best classified as other_material given the absence of a dedicated taxonomy entry for credit facility amendments or refinancings.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-05-21
Item 5.02
C. Taylor Pickett (CEO) and Robert O. Stephenson (CFO) are departing the company, effective October 1, 2026 and August 1, 2026 respectively. The filing discloses transition and consulting agreements for both executives, representing a material change in the company's top leadership.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-05-21
Item 7.01
ClearSign Technologies disclosed quarterly financial results for the quarter ended March 31, 2026 via a press release issued on May 20, 2026, along with a conference call transcript discussing the results.
View raw filing on EDGAR →
8-K
Other material
confidence 85%
filed 2026-05-21
Item 8.01
Adagio Medical submitted a Premarket Approval (PMA) application to the FDA for its vCLAS® Ventricular Ablation System, a significant regulatory milestone for a medical device company. This event is material to investors as FDA approval is a critical path to commercialization and revenue generation, but it does not fit neatly into the more specific event categories (not an earnings release, M&A activity, impairment, litigation, or other defined types). The submission of a major regulatory application represents a material corporate development warranting disclosure under Item 8.01.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-21
The filing discloses the appointment of Troy Taylor, age 54, to the position of Chief Operating Officer (COO) effective May 20, 2026. This is a material executive appointment under Item 5.02, as the COO is a senior officer responsible for leadership and strategic direction. The filing explicitly states no material compensatory arrangements were entered into, making the appointment itself—not compensation—the principal disclosed event.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
The filing discloses Item 5.07 results from Walker & Dunlop's 2026 Annual Meeting of Stockholders held on May 19, 2026, including voting outcomes on three matters: election of eight directors, ratification of KPMG LLP as independent auditor, and an advisory vote on executive compensation. These are standard shareholder vote results that materially inform investors about board composition and governance approvals.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-05-21
Item 7.01
The filing discloses a "proposed transaction between VYNE and Yarrow" with an S-4 registration statement (File No. 333-294804) filed with the SEC, indicating a material merger or acquisition. The disclosure of an investor presentation by Yarrow Bioscience in connection with this transaction, combined with explicit references to proxy solicitation materials and stockholder voting, confirms this is M&A activity requiring 8-K disclosure under Item 1.01 or related provisions.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder vote results from the Annual Meeting of Stockholders held on May 21, 2026, reporting the election of directors (James J. Brady, IV and Eric J. Heagy) and ratification of Wipfli LLP as independent auditor. Item 5.07 is the designated Item for shareholder vote results, and the filing presents final vote tallies for each matter submitted to stockholders.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-21
Item 8.01
The filing discloses entry into material financing arrangements: an Indenture Supplement dated May 28, 2026 for issuance of "Offered Notes" and a Risk Retention Agreement among First National Bank of Omaha, First National Funding LLC, and First National Master Note Trust. While this involves debt issuance and securitization activity, the Item 8.01 classification and absence of explicit M&A language make it distinct from standard ma_activity. The disclosure of note offerings and related indenture supplements would materially affect investor assessment of the registrant's capital structure and financing activities.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-21
Item 8.01
The disclosure announces initial clinical trial data (Duravelo-2) for a candidate therapeutic in metastatic urothelial cancer presented at ASCO. For a clinical-stage or development-focused biopharmaceutical company, positive or significant clinical data announcements are material to investors assessing pipeline progress and regulatory prospects. However, this does not fit neatly into the standard taxonomy categories (not earnings, M&A, impairment, litigation, etc.), warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 5.03
GCI Liberty, Inc. changed its corporate name to Liberty Capital Corporation effective May 21, 2026, through amendments to its Articles of Incorporation and Bylaws. The name change does not affect security holders' rights, trading symbols (GLIBA, GLIBB, GLIBK), or CUSIP numbers.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-05-21
Item 5.07
This Item 5.07 discloses the results of a special stockholder meeting held on May 21, 2026, where shareholders voted on the approval of a merger agreement with AC Residential Acquisition LP and related transactions. The Merger Proposal received overwhelming approval (76,820,975 FOR votes vs. 18,230 AGAINST), representing a material change of control event. The filing explicitly presents voting results for multiple proposals, which is the core disclosure required under Item 5.07.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-05-21
Item 8.01
Black Diamond Therapeutics announced positive Phase 2 clinical trial results for silevertinib in frontline NSCLC patients with EGFR non-classical mutations, demonstrating a preliminary median progression-free survival of 15.2 months, an objective response rate of 60%, and no new safety signals.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear Item 5.07 disclosure of shareholder vote results from the 2026 Annual Meeting held on May 20, 2026. The filing reports voting outcomes on four proposals: election of seven directors, ratification of the independent auditor (EisnerAmper LLP), advisory vote on named executive officer compensation, and approval of a stock option exchange program. The detailed vote tallies for each proposal and nominee are the hallmark of shareholder_vote_results classification.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-21
Item 8.01
VIAVI Solutions conducted a public offering of 11,111,111 shares of common stock at $45.00 per share, with underwriters exercising an additional 1,666,666 shares under the greenshoe option, generating approximately $557.2 million in net proceeds. This is a material registered equity issuance that dilutes existing shareholders and materially affects the company's capital structure and cash position.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 3.03
CarParts.com implemented a 1-for-10 reverse stock split, effective May 25, 2026, following stockholder approval on May 11, 2026. The reverse split modifies the company's capital structure, affects share count and trading mechanics, and results in a new CUSIP number.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-05-21
Item 1.01
The filing discloses entry into material definitive agreements in connection with the issuance of Asset Backed Notes by Mercedes-Benz Auto Receivables Trust 2026-1 on May 20, 2026. This represents a material securitization transaction involving the creation and issuance of structured debt securities backed by auto receivables, which constitutes a material financing activity requiring Item 1.01 disclosure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-21
Item 8.01
CareTrust REIT completed a public offering of 12.5 million firm shares plus 1.875 million optional shares of common stock at $40.225 per share, totaling approximately 14.375 million shares. The filing discloses the underwriting agreement, exercise of the option, and forward sale agreements executed on May 20-21, 2026. This is a material dilutive equity issuance that would significantly affect shareholder ownership and the total mix of information available to investors.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This Item 5.07 filing discloses the results of three shareholder votes at Bank7 Corp.'s annual meeting held May 20, 2026: election of seven directors, ratification of RSM US LLP as independent auditor for 2026, and advisory approval of 2025 named executive officer compensation. The detailed vote tallies (FOR, AGAINST, ABSTAIN, and broker non-votes) for each proposal are the core disclosure, which is the defining characteristic of shareholder_vote_results.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-05-21
Item 5.02
The Board approved a new Change in Control Employment Agreement with Vincent P. Berger II, Executive Vice President and Chief Financial Officer, effective June 1, 2026, detailing severance benefits, eligibility triggers, and compensation arrangements in the event of a change in control and termination.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
HNI Corporation's annual meeting of shareholders held on May 20, 2026 resulted in the election of three directors (Hartnett, Porcellato, and Sivajee), ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a classic Item 5.07 disclosure of shareholder meeting results held on May 20, 2026. The filing presents voting tallies for three proposals: election of 12 directors (with individual vote counts for each nominee), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material governance disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
Insulet Corp held its 2026 Annual Meeting of Stockholders on May 20, 2026, with voting results disclosed for three proposals: election of three Class I directors (Luciana Borio, Michael R. Minogue, Timothy C. Stonesifer), advisory approval of executive compensation (Say-on-Pay), and ratification of PricewaterhouseCoopers LLP as independent auditor.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-21
Item 5.03
Insulet Corp amended and restated its Bylaws to establish exclusive forum selection provisions for derivative actions, fiduciary duty claims, and Securities Act claims, affecting shareholders' litigation rights and corporate governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a standard Item 5.07 disclosure of shareholder voting results from the 2026 Annual Meeting held on May 19, 2026. The filing reports results for five proposals: election of seven directors, approval of an amendment to the 2024 Omnibus Equity Incentive Plan, advisory approval of executive compensation, advisory approval of compensation vote frequency, and ratification of Cherry Bekaert LLP as independent auditors. All proposals passed with substantial majorities, making this a routine but material shareholder governance disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
Aebi Schmidt held its Annual Meeting on May 21, 2026, with shareholders voting on 11 proposals including election of directors, approval of audited financial statements, dividend distribution, and executive compensation matters. All proposals were approved by shareholders with strong majorities.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-05-21
Item 5.02
Shareholders approved the Aebi Schmidt Equity Incentive Plan, which authorizes the Board to grant restricted share units, performance share units, and restricted shares to executives, employees, and non-executive Board members, with 3.5 million shares authorized and performance-based incentive provisions.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-05-21
Item 8.01
Beta Bionics announced an updated commercialization timeline for its lead product candidate, Mint ACE insulin pump, expecting full commercialization by end of Q2 2027 subject to FDA clearance. This material product development milestone affects investor assessment of the company's near-term revenue prospects and regulatory progress.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-05-21
Item 2.01
RTB Digital completed a merger transaction, resulting in a change of control of the registrant. The merger involved the reconstitution of the Board with multiple director resignations and appointments, and the Board was resized to seven members.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-05-21
Item 5.02
Following the merger closing on May 21, 2026, RTB Digital appointed four new executive officers: James Heckman as CEO, Aly Madhavji as CFO, George Oliva as Chief Accounting Officer, and William Sornsin as COO.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-21
Item 3.02
RTB Digital issued approximately 13.1 million unregistered shares pursuant to Section 4 exemptions, comprising 7.7 million shares from convertible debt conversion, 2.1 million shares from warrant exercise, and 3.4 million shares from option exercise, materially diluting existing shareholders.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-21
Item 7.01
This Item 7.01 disclosure presents BREIT's Q1 2026 quarterly update, including performance metrics (+2.0% net return), portfolio composition, and strategic positioning. While it contains performance data and forward-looking commentary on real estate markets and BREIT's investment strategy, it does not constitute a formal earnings release (no complete financial statements or standardized earnings metrics), nor does it fit cleanly into other specific event categories. The disclosure is material to investors as it provides substantive updates on fund performance, portfolio allocation, and capital deployment, but the format and content are more consistent with a general investor update than a traditional earnings announcement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-05-21
Item 2.02
The filing discloses a press release announcing "operating and financial results for its first quarter ended May 2, 2026," which is a standard quarterly earnings release. The press release is attached as Exhibit 99.1 and incorporated by reference, consistent with Item 2.02 earnings disclosures. This is material to investors assessing the company's financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-05-21
Item 2.02
The filing discloses financial results for the first quarter ended April 25, 2026 via a press release furnished as Exhibit 99.1. This is a classic earnings release disclosure under Item 2.02, which is material to investors as it provides quarterly financial performance information essential to assessing the registrant's operating results and financial condition.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-05-21
Item 2.02
The filing discloses a press release announcing financial results for the quarter ended March 31, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). This is a standard earnings release disclosure with the press release furnished as Exhibit 99.1, which is material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-05-21
Item 1.01
Equity Residential entered into an Agreement and Plan of Merger with AvalonBay Communities, Inc., structured as an all-stock merger-of-equals transaction with an exchange ratio of 2.793 Equity Residential Common Shares per AvalonBay share. Both boards unanimously approved the transaction, which constitutes a material acquisition and change of control requiring shareholder approval, supported by a $2 billion bridge financing commitment.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 75%
filed 2026-05-21
Item 5.02
Equity Residential amended and restated the Change in Control Agreement with Mark J. Parrell, modifying his severance formula to 2.25x base salary plus target bonus and equity grant, plus 27 months of benefits continuation in connection with the merger transaction.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-05-21
Item 5.02
Matthew J. Peterson, Executive Vice President and President of Behavioral Health, resigned effective June 19, 2026, after seven years with the company. While the filing also addresses compensatory arrangements (forfeiture of unvested equity and termination of benefits), the principal disclosed action is Peterson's departure from a senior executive role overseeing a major division. The CEO will assume interim responsibilities while a permanent replacement is sought, indicating material operational impact.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 7.01
The FDA reclassified non-invasive bone growth stimulators from Class III to Class II, triggering CMS reimbursement changes that reduce Medicare reimbursement by approximately 10% for HCPCS codes E0747, E0748, and E0760. This regulatory action materially impacts Orthofix's financial outlook, forcing the company to lower full-year 2026 net sales guidance to $838–$848 million and adjusted EBITDA to $90–$93 million, and to withdraw its three-year financial targets. While this is a material event affecting investor assessment, it does not fit neatly into the more specific categories (it is neither a restatement, impairment, covenant breach, nor litigation), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-05-21
Item 1.01
Corbus Pharmaceuticals appointed Nishant Saxena as Chief Business Officer effective May 21, 2026, under a two-year employment agreement with base salary of $470,000 and equity grants of 192,300 stock options and 58,300 RSUs.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-05-21
Item 5.02
Brent Pfeiffenberger received equity compensation awards in connection with his Board appointment: a nonqualified stock option for 24,700 shares and a restricted stock unit award for 7,500 shares, both vesting over three years.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-05-21
Item 8.01
Devon Energy completed the acquisition of 16,300 net undeveloped acres in the Delaware Basin for approximately $2.6 billion, a material transaction representing significant expansion of the company's oil and gas asset base.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-05-21
Item 5.02
Michael A. Shriner's separation from his positions as President and Chief Executive Officer of BCB Bancorp and its subsidiary, along with his departure from both boards, is the principal disclosed action. While the filing also mentions Ryan Blake's appointment as Interim President and CEO, the prose centers on Shriner's departure as the triggering event. The departure of a CEO is material to investors assessing the registrant's leadership and governance.
View raw filing on EDGAR →